- Home
- GOF vs PTGX Comparison
GOF vs PTGX Comparison
Compare GOF & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOF
- PTGX
- Stock Information
- Founded
- GOF 2006
- PTGX 2006
- Country
- GOF United States
- PTGX United States
- Employees
- GOF N/A
- PTGX N/A
- Industry
- GOF Finance/Investors Services
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- GOF Finance
- PTGX Health Care
- Exchange
- GOF Nasdaq
- PTGX Nasdaq
- Market Cap
- GOF 2.7B
- PTGX 3.7B
- IPO Year
- GOF N/A
- PTGX 2016
- Fundamental
- Price
- GOF $14.91
- PTGX $58.45
- Analyst Decision
- GOF
- PTGX Strong Buy
- Analyst Count
- GOF 0
- PTGX 9
- Target Price
- GOF N/A
- PTGX $70.44
- AVG Volume (30 Days)
- GOF 789.2K
- PTGX 915.6K
- Earning Date
- GOF 01-01-0001
- PTGX 11-06-2025
- Dividend Yield
- GOF 15.42%
- PTGX N/A
- EPS Growth
- GOF N/A
- PTGX N/A
- EPS
- GOF N/A
- PTGX 0.80
- Revenue
- GOF N/A
- PTGX $209,180,000.00
- Revenue This Year
- GOF N/A
- PTGX N/A
- Revenue Next Year
- GOF N/A
- PTGX $185.11
- P/E Ratio
- GOF N/A
- PTGX $72.62
- Revenue Growth
- GOF N/A
- PTGX N/A
- 52 Week Low
- GOF $10.96
- PTGX $33.31
- 52 Week High
- GOF $16.76
- PTGX $61.89
- Technical
- Relative Strength Index (RSI)
- GOF 51.67
- PTGX 52.03
- Support Level
- GOF N/A
- PTGX N/A
- Resistance Level
- GOF $15.11
- PTGX $60.40
- Average True Range (ATR)
- GOF 0.08
- PTGX 2.58
- MACD
- GOF -0.56
- PTGX -2.28
- Stochastic Oscillator
- GOF 98.31
- PTGX 94.44
About GOF Guggenheim Strategic Opportunities Fund of Beneficial Interest
Guggenheim Strategic Opportunities Fund is a diversified, closed-end management investment company. The investment objective of the firm is to maximize total return through a combination of current income and capital appreciation. The Fund seeks to combine a credit-managed fixed-income portfolio with access to a diversified pool of alternative investments and equity strategies.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.